Published in Hosp Pharm on June 01, 2016
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol (1989) 6.86
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol (2006) 4.97
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol (2010) 3.46
Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol (2005) 2.00
Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol (1999) 1.87
Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol (2006) 1.44
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer (2001) 1.37
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 1.36
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev (1995) 1.36
Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol (1993) 1.30
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol (2009) 1.18
Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs (1998) 1.17
Hypersensitivity to antineoplastic agents. Curr Pharm Des (2008) 1.16
A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer (1994) 1.14
A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol (1993) 1.13
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer (2012) 1.11
The severity and pattern of emesis following different cytotoxic agents. Oncology (1996) 1.05
Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia. Cancer Chemother Pharmacol (2005) 1.04
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol (2008) 1.02
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol (2011) 1.00
Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors. Lung Cancer (2012) 1.00
Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol (2005) 0.99
Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs (1997) 0.98
Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol (2009) 0.96
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol (2009) 0.94
Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm (1987) 0.91
Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial. Anticancer Res (2009) 0.89
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Eur J Cancer (2014) 0.88
Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. Oncology (1996) 0.84
Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer (2009) 0.82
Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags. J Oncol Pharm Pract (2014) 0.80
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. Oncology (2008) 0.78
Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum. Gynecol Oncol (2008) 0.77
A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer. Jpn J Clin Oncol (2015) 0.77
Drug monographs: dabrafenib and trametinib. Hosp Pharm (2013) 0.82
Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost. J Oncol Pharm Pract (2005) 0.80
Drug monographs: bosutinib and regorafenib. Hosp Pharm (2013) 0.76
Cost savings realized by use of the PhaSeal(®) closed-system transfer device for preparation of antineoplastic agents. J Oncol Pharm Pract (2013) 0.76
Pentostatin, Cyclophosphamide and Rituximab (PCR) Regimen. Hosp Pharm (2016) 0.75
Alectinib, Ceritinib, Elotuzumab, and Venetoclax. Hosp Pharm (2016) 0.75
Drug Monographs: Atezolizumab and Everolimus. Hosp Pharm (2016) 0.75
Lenvatinib and Palbociclib. Hosp Pharm (2015) 0.75
Ado-trastuzumab emtansine and radium 223 dichloride. Hosp Pharm (2013) 0.75
Drug monographs: ibrutinib and ramucirumab. Hosp Pharm (2014) 0.75
Drug monographs: pomalidomide and ponatinib. Hosp Pharm (2013) 0.75
Drug Monographs: Olaratumab and Rucaparib. Hosp Pharm (2017) 0.75
Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL). Hosp Pharm (2016) 0.75
Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors. Hosp Pharm (2017) 0.75
Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma. Hosp Pharm (2017) 0.75
Idelalisib and Rituximab Regimen. Hosp Pharm (2017) 0.75
Drug Monographs: Ixazomib and Necitumumab. Hosp Pharm (2016) 0.75
Nivolumab and Olaparib. Hosp Pharm (2015) 0.75
Cabazitaxel and Prednisone Regimen for Prostate Cancer. Hosp Pharm (2015) 0.75
Drug Monographs: Daratumumab and Osimertinib. Hosp Pharm (2016) 0.75
Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer. Hosp Pharm (2014) 0.75
Survey of carboplatin dosing strategies in oncology practices. J Am Pharm Assoc (2003) (2013) 0.75